Abstract: The present invention relates to a use of a natural compound Anisomelic acid extracted from Anisomeles indica O. Kuntze in the preparation of pharmaceutical compositions for inhibiting the infection and replication of novel coronaviruses and the mutant strains (SARS-CoV-2 variants) thereof, the Anisomelic acid is a compound comprising a chemical structural Formula I, the pharmaceutical composition includes a safe and effective amount of Anisomelic acid, that is, the pharmaceutical composition is a combination of a safe and effective amount of Anisomelic acid and its pharmaceutically acceptable salt or carrier thereof.

Abstract: A method for asymmetric synthesis of (?)-Anisomelic Acid is provided in the present invention, a chiral compound (?)-Costunolide is used as a starting material, a key intermediate is obtained by a regioselective ozone decomposition reaction, then carbon chain extension is performed by a Horner-Wadsworth-Emmons (HWE) reaction and a Peterson olefination reaction, and a (?)-anisomelic acid fourteen-membered carbocyclic skeleton is constructed by a ring-closing metathesis (RCM) reaction, laying an important foundation for subsequent (?)-anisomelic acid biological activity research, in the synthesis route, various (?)-anisomelic acid analogs can also be obtained from the key intermediate, the reaction operations in the synthesis route are simple and the present invention can be widely popularized and used.

Abstract: A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.